TY - JOUR AU - Marek Trnĕný, AU - Gregor Verhoef, AU - Martin JS Dyer, AU - Dina Ben Yehuda, AU - Caterina Patti, AU - Miguel Canales, AU - Andrés Lopez, AU - Farrukh T Awan, AU - Paul G Montgomery, AU - Andrea Janikova, AU - Anna M Barbui, AU - Kazimierz Sulek, AU - Maria J Terol, AU - John Radford, AU - Anna Guidetti, AU - Massimo Di Nicola, AU - Laure Siraudin, AU - Laurence Hatteville, AU - Sandrine Schwab, AU - Corina Oprea, AU - Alessandro M Gianni, PY - 2018/07/31 Y2 - 2024/03/28 TI - A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy JF - Haematologica JA - haematol VL - 103 IS - 8 SE - Articles DO - 10.3324/haematol.2017.168401 UR - https://haematologica.org/article/view/8557 SP - 1351-1358 AB - This phase II, single-arm, multicenter study examined the efficacy and safety of coltuximab ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented (de novo or transformed) relapsed or refractory diffuse large B-cell lymphoma who had previously received rituximab-containing immuno-chemotherapy. Patients had received a median of 2.0 (range 0-9) prior treatment regimens for diffuse large B-cell lymphoma and almost half (45.9%) had bulky disease (≥1 lesion >5 cm) at trial entry. Patients received coltuximab ravtansine (55 mg/m2) in 4 weekly and 4 biweekly administrations until disease progression or unacceptable toxicity. Forty-one patients were eligible for inclusion in the per protocol population. Overall response rate (International Working Group criteria) in the per protocol population, the primary end point, was 18/41 [43.9%; 90% confidence interval (CI:) 30.6-57.9%]. Median duration of response, progression-free survival, and overall survival (all treated patients) were 4.7 (range 0.0-8.8) months, 4.4 (90%CI: 3.02-5.78) months, and 9.2 (90%CI: 6.57-12.09) months, respectively. Common non-hematologic adverse events included asthenia/fatigue (30%), nausea (23%), and diarrhea (20%). Grade 3-4 adverse events were reported in 23 patients (38%), the most frequent being hepatotoxicity (3%) and abdominal pain (3%). Eye disorders occurred in 15 patients (25%); all were grade 1-2 and none required a dose modification. Coltuximab ravtansine monotherapy was well tolerated and resulted in moderate clinical responses in pre-treated patients with relapsed/refractory diffuse large B-cell lymphoma. (Registered at: clinicaltrials.gov identifier: 01472887) ER -